ALT
Price
$6.99
Change
-$0.01 (-0.14%)
Updated
Jan 31, 01:27 PM (EDT)
Capitalization
494.32M
55 days until earnings call
KRYS
Price
$159.13
Change
+$3.06 (+1.96%)
Updated
Jan 31, 11:13 AM (EDT)
Capitalization
4.5B
31 days until earnings call
Ad is loading...

ALT vs KRYS

Header iconALT vs KRYS Comparison
Open Charts ALT vs KRYSBanner chart's image
Altimmune
Price$6.99
Change-$0.01 (-0.14%)
Volume$5.98K
Capitalization494.32M
Krystal Biotech
Price$159.13
Change+$3.06 (+1.96%)
Volume$900
Capitalization4.5B
ALT vs KRYS Comparison Chart
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. KRYS commentary
Jan 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Buy and KRYS is a Buy.

Ad is loading...
COMPARISON
Comparison
Jan 31, 2025
Stock price -- (ALT: $7.00 vs. KRYS: $156.07)
Brand notoriety: ALT and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 57% vs. KRYS: 56%
Market capitalization -- ALT: $494.32M vs. KRYS: $4.5B
ALT [@Biotechnology] is valued at $494.32M. KRYS’s [@Biotechnology] market capitalization is $4.5B. The market cap for tickers in the [@Biotechnology] industry ranges from $379.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2.47B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileKRYS’s FA Score has 1 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • KRYS’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 6 TA indicator(s) are bullish while KRYS’s TA Score has 5 bullish TA indicator(s).

  • ALT’s TA Score: 6 bullish, 2 bearish.
  • KRYS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, ALT is a better buy in the short-term than KRYS.

Price Growth

ALT (@Biotechnology) experienced а -0.85% price change this week, while KRYS (@Biotechnology) price change was +0.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.84%. For the same industry, the average monthly price growth was +1.79%, and the average quarterly price growth was +5.50%.

Reported Earning Dates

ALT is expected to report earnings on May 20, 2025.

KRYS is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-0.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.5B) has a higher market cap than ALT($494M). KRYS YTD gains are higher at: -0.377 vs. ALT (-2.913). KRYS has higher annual earnings (EBITDA): 181M vs. ALT (-103.19M). KRYS has more cash in the bank: 588M vs. ALT (139M). ALT has less debt than KRYS: ALT (1.77M) vs KRYS (7.48M). KRYS has higher revenues than ALT: KRYS (242M) vs ALT (52K).
ALTKRYSALT / KRYS
Capitalization494M4.5B11%
EBITDA-103.19M181M-57%
Gain YTD-2.913-0.377773%
P/E RatioN/A87.68-
Revenue52K242M0%
Total Cash139M588M24%
Total Debt1.77M7.48M24%
FUNDAMENTALS RATINGS
ALT vs KRYS: Fundamental Ratings
ALT
KRYS
OUTLOOK RATING
1..100
85
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
82
Overvalued
PROFIT vs RISK RATING
1..100
7923
SMR RATING
1..100
9880
PRICE GROWTH RATING
1..100
5858
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (82) in the Pharmaceuticals Major industry is in the same range as ALT (97) in the Miscellaneous Commercial Services industry. This means that KRYS’s stock grew similarly to ALT’s over the last 12 months.

KRYS's Profit vs Risk Rating (23) in the Pharmaceuticals Major industry is somewhat better than the same rating for ALT (79) in the Miscellaneous Commercial Services industry. This means that KRYS’s stock grew somewhat faster than ALT’s over the last 12 months.

KRYS's SMR Rating (80) in the Pharmaceuticals Major industry is in the same range as ALT (98) in the Miscellaneous Commercial Services industry. This means that KRYS’s stock grew similarly to ALT’s over the last 12 months.

KRYS's Price Growth Rating (58) in the Pharmaceuticals Major industry is in the same range as ALT (58) in the Miscellaneous Commercial Services industry. This means that KRYS’s stock grew similarly to ALT’s over the last 12 months.

KRYS's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that KRYS’s stock grew similarly to ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTKRYS
RSI
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
83%
Momentum
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
75%
Advances
ODDS (%)
Bullish Trend 24 days ago
85%
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 30 days ago
88%
Bearish Trend 30 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 3 days ago
82%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
View a ticker or compare two or three
Ad is loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPHB92.191.33
+1.46%
Invesco S&P 500® High Beta ETF
ACVF45.130.36
+0.80%
American Conservative Values ETF
XHYD37.940.10
+0.27%
BondBloxx US HY Cnsmr N-Cyclcls Sctr ETF
MZZ9.12N/A
N/A
ProShares UltraShort MidCap400
IBTG22.86N/A
N/A
iShares iBonds Dec 2026 Term Tr ETF

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with CLDX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-0.15%
CLDX - KRYS
57%
Loosely correlated
-0.98%
BEAM - KRYS
47%
Loosely correlated
+5.29%
ALT - KRYS
46%
Loosely correlated
+0.72%
ZLDPF - KRYS
45%
Loosely correlated
+0.64%
VCYT - KRYS
44%
Loosely correlated
+3.83%
More